|
HS Code |
193425 |
| Name | 2-Bromo-1,3-Thiazole-5-Carbaldehyde |
| Molecular Formula | C4H2BrNOS |
| Molecular Weight | 192.03 g/mol |
| Appearance | Typically a solid |
| Color | May vary, often off - white to pale yellow |
| Melting Point | Data may vary, needs experimental determination |
| Boiling Point | Data may vary, needs experimental determination |
| Solubility In Water | Low solubility |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, chloroform |
| Density | Data may vary, needs experimental determination |
| Purity | Can be available in different purity levels, e.g., 95%, 98% etc. |
As an accredited 2-Bromo-1,3-Thiazole-5-Carbaldehyde factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of 2 - Bromo - 1,3 - Thiazole - 5 - Carbaldehyde packaged in air - tight glass bottles. |
| Shipping | 2 - Bromo - 1,3 - Thiazole - 5 - Carbaldehyde is a chemical. Shipping should be in well - sealed, corrosion - resistant containers. It must comply with hazardous chemical transportation regulations, ensuring proper labeling and handling to prevent spills and ensure safety. |
| Storage | 2 - Bromo - 1,3 - thiazole - 5 - carbaldehyde should be stored in a cool, dry, and well - ventilated area. Keep it away from heat sources, open flames, and oxidizing agents. Store in a tightly sealed container to prevent exposure to air and moisture, which could lead to degradation. It's advisable to store it in a dedicated chemical storage cabinet for proper containment and safety. |
In the commercial synthesis of the FLT3 inhibitor quizartinib (Vanflyta®), 2-bromo-1,3-thiazole-5-carbaldehyde serves as the heterocyclic aldehyde building block that undergoes regiospecific cyclocondensation with 4-nitro-1,2-phenylenediamine to forge the thiazolo[3,2‑a]benzimidazole core. Batches produced under ICH Q7 active pharmaceutical ingredient GMP require the aldehyde to be charged at a molar ratio of 1.00 ± 0.02 relative to the diamine; excursions beyond a 1.10 excess lead to intractable dimerization and a sharp rise in the bis‑adduct impurity that is resistant to recrystallization from methylcyclohexane/ethyl acetate. The cyclization is executed in absolute ethanol under nitrogen at 78–80 °C for 36–48 h, monitored by in-process HPLC (USP <621>) until the residual aldehyde drops below 0.15 % area. After aqueous quench, the nitro intermediate is reduced in a Hastelloy C‑276 autoclave with 5 % Pd/C (50 % water‑wet, 0.05 wt% Pd relative to substrate) under 3.5‑4.0 bar hydrogen pressure at 55 °C; the catalyst is filtered through a 0.2 µm polypropylene cartridge to meet palladium content below 10 ppm by ICP‑MS (USP <730>). Subsequent urea formation with 4‑(tert‑butyl)phenyl isocyanate and Suzuki coupling with 3‑(tert‑butyl)isoxazole‑5‑boronic acid pinacol ester in the presence of Pd(dppf)Cl₂ (1.2 mol%) and K₂CO₃ in THF:H₂O 4:1 at 65 °C delivers the API, with residual solvent limits conforming to USP <467> Class 2 criteria. The terminal dosage form is quizartinib dihydrochloride film‑coated tablets, 17.7 mg and 26.5 mg, approved for FLT3‑ITD‑positive acute myeloid leukemia.
What Happens to Crystallinity When 2‑Bromo‑1,3‑thiazole‑5‑carbaldehyde Is Incorporated into Imine‑Linked COFs?Two‑dimensional imine‑linked covalent organic frameworks that employ 2‑bromo‑1,3‑thiazole‑5‑carbaldehyde as a brominated aldehyde monomer show a distinct crystallinity‑fragmentation trade‑off governed by the steric bulk of the ortho‑bromine substituent. For a prototypical COF constructed from 1,3,5‑tris(4‑aminophenyl)benzene and the brominated thiazole aldehyde in a molar ratio of amine‑to‑aldehyde 1.0 : 1.8, solvothermal synthesis in a sealed Pyrex tube filled with mesitylene:dioxane (4:1 v/v) and 6 M aqueous acetic acid (0.4 mL per 1.0 mmol monomer) at 120 °C for 72 h yields a BET surface area of 1 120 m²·g⁻¹ (N₂, 77 K, ISO 9277:2010), approximately 18 % lower than the analogous non‑brominated phenyl‑aldehyde COF, attributable to pore occlusion by the halogen. The downstream production process employs Soxhlet extraction with anhydrous tetrahydrofuran for 48 h followed by activation under dynamic vacuum at 120 °C for 24 h to reach the permanent porosity needed for membrane casting. Post‑synthetic modification exploits the retained bromine handle; treatment with lithium diphenylphosphide in dry THF at −78 °C to 25 °C grafts phosphine donors onto the framework walls, allowing subsequent coordination of Rh(I) or Pd(II) species for heterogeneous catalysis under continuous flow. The terminal product is a supported catalytic membrane or a fixed‑bed cartridge for cross‑coupling reactions in pharmaceutical fine‑chemical streams, where leachable metal must remain below 1.0 ppm in the product stream per REACH Annex XVII restrictions. Compliance for EU import requires documentation according to (EC) No 1907/2006 and analytical verification via XPS and ICP‑OES.The Knoevenagel condensation of 2‑bromo‑1,3‑thiazole‑5‑carbaldehyde with 3‑ethyl‑2‑thioxothiazolidin‑4‑one (ethylrhodanine) in a mixture of chloroform and pyridine (20:1 v/v) at 65 °C for 8 h produces the strong electron‑withdrawing end‑cap (E)‑3‑ethyl‑5‑((5‑bromothiazol‑2‑yl)methylene)‑2‑thioxothiazolidin‑4‑one, used in non‑fullerene acceptors for organic photovoltaics. In a typical acceptor formulation, 2.2 equivalents of this brominated thiazole‑rhodanine unit are coupled via Stille cross‑coupling to a distannylated indacenodithienothiophene (IDTT‑SnMe₃) core in degassed toluene with Pd₂(dba)₃ (2 mol%) and P(o‑tol)₃ (8 mol%) at 110 °C for 18 h. The reaction mixture is quenched with aqueous potassium fluoride to precipitate tin residues, and the crude acceptor is purified by column chromatography (SiO₂, CHCl₃:hexane 1:1) and recrystallized from chlorobenzene to achieve > 99 % purity by HPLC‑UV. Device processing in a glove‑box integrates the acceptor with the donor polymer PM6 (PBDB‑T‑2F) at a 1:1.2 wt/wt ratio from a 16 mg·mL⁻¹ chlorobenzene solution containing 0.5 vol% diphenyl ether, spin‑coated onto ITO‑glass pre‑coated with PEDOT:PSS, and capped with a PFN‑Br cathode interlayer and evaporated Al electrode. Power conversion efficiencies reported in the open literature for this acceptor family fall in the 10–13 % range under AM1.5G illumination (100 mW·cm⁻², IEC 60904‑3), limited by the moderate electron mobility of the thiazole‑rhodanine terminus relative to fused‑ring dicyanomethylene alternatives. The final component is a flexible or rigid organic photovoltaic module, subject to environmental stress testing per IEC 61215‑1:2021 for thin‑film terrestrial applications. Materials compliance is governed by ISO 9001:2015 batch documentation and heavy‑metal thresholds per RoHS Directive 2011/65/EU Annex II, where cadmium in the ITO electrode remains below 100 ppm.Scavenging Aldehyde Functionality in Injectable Polyethylene Glycol HydrogelsInjectable polyethylene glycol hydrogels crosslinked via acylhydrazone bonds are fabricated from 8‑arm PEG‑aldehyde generated by Dess‑Martin periodinane oxidation of the parent alcohol, but a more site‑specific approach uses 2‑bromo‑1,3‑thiazole‑5‑carbaldehyde as a heterobifunctional linker that grafts onto thiol‑terminated 4‑arm PEG via base‑catalyzed thiol‑bromo displacement in dimethylformamide with triethylamine (1.2 equiv) at 25 °C for 6 h, yielding a macromer that carries the intact thiazole aldehyde. The stoichiometric ratio of aldehyde macromer to the complementary poly(ethylene glycol) dihydrazide crosslinker is maintained at 0.9:1.0 (aldehyde:hydrazide) to ensure complete gelation within 120 s at 37 °C at a total solids content of 8 wt% in phosphate‑buffered saline (pH 7.4). Sterile mixing is performed in a dual‑barrel syringe fitted with a 12‑element static mixer (0.35 mL dead volume); the dynamic oscillatory rheology (strain 1 %, frequency 1 Hz) of the curing hydrogel on a Discovery HR‑2 rheometer with a 20 mm parallel‑plate geometry shows a storage modulus plateau at 4.2 ± 0.3 kPa after 15 min. The crosslinked network is designed as a temporary vitreous substitute or a surgical sealant, and its compliance with ISO 10993‑5:2009 for direct‑contact cytotoxicity is required; endotoxin levels in the precursor solutions must not exceed 0.25 EU·mL⁻¹ tested per USP <85>. Published data for this specific thiazole‑aldehyde configuration remain limited to preclinical porcine vitrectomy models where intraocular pressure was maintained over 90 days without significant inflammatory infiltrate. |
Competitive 2-Bromo-1,3-Thiazole-5-Carbaldehyde prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Substrate | Oxidative Addition TOF (h⁻¹)⁽¹⁾ | Typical Pd Loading (mol%) | Selectivity (C–Br/C–CHO)⁽²⁾ |
|---|---|---|---|
| 2‑Bromo‑1,3‑thiazole‑5‑carbaldehyde | 12.4 ± 0.6 | 0.5 | >95:5 |
| 2‑Chloro‑1,3‑thiazole‑5‑carbaldehyde | 1.9 ± 0.3 | 2.0 | >98:2 |
| 5‑Bromo‑1,3‑thiazole‑2‑carbaldehyde | 6.1 ± 0.5 | 1.0 | 92:8 |
| Parameter | Limit | Test Method |
|---|---|---|
| Appearance | White to off‑white crystalline powder | Visual inspection |
| Purity (HPLC, area‑%) | ≥98.0% | In‑house HPLC‑UV, validated per ICH Q2(R1) |
| Single largest impurity | ≤0.5% | HPLC‑UV |
| Melting range | 77.0–81.0°C | DSC, ASTM E794, onset and peak |
| Water content (K.F.) | ≤0.30% | Coulometric K.F., ASTM E203 |
| Residual solvents (total) | ≤0.20% | GC‑HS, USP <467> options |
| Sulfated ash | ≤0.10% | USP <281> |
| Bromide ion (ion chromatography) | ≤100 ppm | DIN EN ISO 10304‑1 |